Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.

Blood advances - 10 Mar 2026

Li Na, Liu Yicen, Zhang Linna, Guo Saisai, Wu Zhihao, Xu Yan, Yang Ming, Kong Jixia, Che Yuxuan, Shao Kun, Yang Hong

Abstract excerpt

ABSTRACT: Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissues, emerges as a therapeutic target. The NAMPT inhibitor KPT-9274 reduced viability and induced apoptosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytokines

Share to DNA Damage

Share to Lymphoma, Mantle-Cell

Share to Nicotinamide Phosphoribosyltransferase

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41428986
DOI: 10.1182/bloodadvances.2025016765
PMCID: PMC12964014

Genes

TP53
NAMPT
BCR
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.PMID 41428986Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.Semantic proximity Read ↗

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.Semantic proximity Read ↗

Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.Semantic proximity Read ↗

PRMT5 supports multiple oncogenic pathways in mantle cell lymphomaSemantic proximity Read ↗

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patientsSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read ↗

Pan-cancer analysis combined with experiments predicts NNMT as a therapeutic target for human cancersSemantic proximity Read ↗

Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic NichesSemantic proximity Read ↗

Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerSemantic proximity Read ↗

Mechanisms of resistance to NAMPT inhibitors in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.